Table 4.
Case clustering in two groups according to demographics, clinical variables and symptoms reported
| Cluster 1 | Cluster 2 | p | |
|---|---|---|---|
| N (all: 1154) | 840 | 314 | |
| Age (years, mean, SD) | 57.5 (14.2) | 64.6 (11.1) | < 0.001 |
| Women (n, %) | 474 (56.5%) | 123 (39.2%) | < 0.001 |
| Omicron phase of the pandemic (n, %) | 301 (35.8%) | 30 (9.6%) | < 0.001 |
| Current smoking (n, %) | 97 (11.5%) | 20 (6.4%) | 0.009 |
| Comorbidities (mean number, SD) | 1.2 (1.2) | 1.9 (1.6) | < 0.001 |
| Acute infection severe or critical (n, %) | 228 (27.1%) | 313 (99.7%) | < 0.001 |
| CPAP, mechanical ventilation or ECMO (n, %) | 0 (0%) | 311 (99.0%) | < 0.001 |
| Hospitalised during acute phase (n, %) | 414 (49.3%) | 314 (100%) | < 0.001 |
| Admitted to intensive care unit (n, %) | 6 (0.7%) | 110 (35.0%) | < 0.001 |
| Fatigue | 496 (59.0%) | 169 (53.8%) | 0.110 |
| Dyspnea | 383 (45.6%) | 187 (59.6%) | < 0.001 |
| Sleep disturbances | 193 (23.0%) | 66 (21.0%) | 0.478 |
| Memory loss | 170 (20.2%) | 66 (21.0%) | 0.770 |
| Joint pain or swelling | 145 (17.3%) | 55 (17.5%) | 0.919 |
| Muscle pain | 148 (17.6%) | 47 (15.0%) | 0.285 |
| Difficult concentration | 149 (17.7%) | 40 (12.7%) | 0.041 |
| Cough | 120 (14.3%) | 36 (11.5%) | 0.212 |
| Anxiety | 114 (13.6%) | 35 (11.1%) | 0.274 |
| Taste reduction | 107 (12.7%) | 31 (9.9%) | 0.182 |
| Smell reduction | 104 (12.4%) | 32 (10.2%) | 0.305 |
| Palpitations, tachycardia | 106 (12.6%) | 27 (8.6%) | 0.057 |
| Depressed mood | 90 (10.7%) | 43 (13.7%) | 0.158 |
| Skin disorders, alopecia | 57 (6.8%) | 29 (9.2%) | 0.158 |
| Thoracic pain | 90 (10.7%) | 25 (8.0%) | 0.165 |
| Paresthesia | 64 (7.6%) | 45 (14.3%) | < 0.001 |
| Brain fog | 72 (8.6%) | 19 (6.1%) | 0.157 |
| Headache | 68 (8.1%) | 12 (3.8%) | 0.011 |
| Disorders of equilibrium or gait | 52 (6.2%) | 16 (5.1%) | 0.482 |
CPAP continuous positive airway pressure, ECMO extracorporeal membrane oxygenation